Skip to main content
Caplight Logo









EntoZyme

EntoZyme

Private
SydneyFrontier & Industrial Techhttps://www.entozyme.com/

Last Round

Seed

Oct 26, 2023

Total Funding Raised

$320,000

Company Overview

EntoZyme is a biotechnology company that develops genetic engineering techniques to process various organic waste streams and produce valuable enzymes and bioactive compounds.

Sector

Frontier & Industrial Tech

Verticals

Biotechnology, Circular Economy, Sustainable Materials, Waste Management

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

synthetic biologygenetic engineeringBlack Soldier FliesBSFwaste-to-valuesynbiobiomanufacturing platforminsect proteinalternative proteinsorganic waste conversionaquaculture feedanimal feed ingredientscircular economyupcycled ingredientsindustrial enzymesinsect farmingsustainable aviation fueldeep tech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EntoZyme Comparables

Compare EntoZyme with similar companies based on industry and business-model similarity.

EntoZyme comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ByBug
85%
BugEra
80%
Schwarz Group
78%

EntoZyme Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedOct 26, 2023

Key People

Founding team and executive leadership

Maciej Maselko

Co-Founder and CEO

Founding Team

EntoZyme Investors

Notable investors and investment history

EntoZyme investors
InvestorRounds
Macquarie University IncubatorSeed
UNSW FoundersSeed
Main Sequence VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 2, 2026

    Monthly visitors increased 145% MoM.

  • Oct 26, 2023

    $320K round led by Main Sequence Ventures.

EntoZyme Filings

Explore SEC and related filing metadata, where available.

EntoZyme filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about EntoZyme's valuation, stock price, and market status.

Is EntoZyme a public or private company?

EntoZyme is a private company.

What is the current stock price of EntoZyme?

EntoZyme is a private company with no public stock price. No recent secondary market data is available.

How much is EntoZyme worth (valuation)?

Valuation information for EntoZyme is not publicly available.

Can I buy EntoZyme stock?

EntoZyme shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was EntoZyme's last funding round?

Funding round information for EntoZyme is not publicly available.

Who are the main investors in EntoZyme?

Investor information for EntoZyme is not publicly disclosed.

Will EntoZyme IPO soon?

No public IPO plans have been announced for EntoZyme.

How can I track EntoZyme secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor EntoZyme's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSydney
Employee Range6
Year Founded2024
Last FundingOct 26, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?